The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Rahul Aggarwal discussing DLL3 and whether target expression determines the method of targeting.

Here, we review key updates in genetic and genomic testing for prostate cancer, including clinical implications of testing for advanced disease, the role of RNA expression tests with emphasis on ...

The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...

Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics. Background: Physical activity (PA), in particular longer duration or higher intensity, may ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...